Humanized M-CSF mice
Genetically modified mice comprising a nucleic acid sequence encoding a human M-CSF protein are provided. Also provided are genetically modified mice comprising a nucleic acid sequence encoding a human M-CSF protein that have been engrafted with human cells such as human hematopoietic cells, and methods for making such engrafted mice. These mice find use in a number of applications, such as in modeling human immune disease and pathogen infection; in in vivo screens for agents that modulate hematopoietic cell development and/or activity, e.g. in a healthy or a diseased state; in in vivo screens for agents that are toxic to hematopoietic cells; in in vivo screens for agents that prevent against, mitigate, or reverse the toxic effects of toxic agents on hematopoietic cells; in in vivo screens of human hematopoietic cells from an individual to predict the responsiveness of an individual to a disease therapy, etc.
1. A method of screening an agent to determine the in-vivo effect of the agent, the method comprising:
(a) contacting a first humanized Macrophage Colony Stimulating Factor (M-CSF) mouse with an agent; and
(b) comparing the first humanized M-CSF mouse to a second humanized M-CSF mouse in the absence of the agent to determine the in-vivo effect of the agent, each of the first and second humanized M-CSF mice comprising:
a nucleic acid sequence incorporated into the genome of the humanized M-CSF mouse, which sequence encodes a human M-CSF protein and is operably linked to the endogenous promoter of the mouse M-CSF gene at the mouse M-CSF locus;
a Recombination Activating Gene 2 (Rag2) gene knock-out and an Interleukin 2 Receptor, Gamma Chain (IL2rg) gene knockout; and
engrafted human hematopoietic cells, wherein each of the first and second humanized M-CSF mice expresses M-CSF RNA encoded by the nucleic acid sequence in bone marrow, spleen, blood, liver, brain, lung, testis and kidney.
2. The method of claim 1 , wherein the comparing comprises comparing the function of the human hematopoietic cells in the first humanized M-CSF mouse contacted with the agent to the function of the human hematopoietic cells in the second humanized M-CSF mouse in the absence of the agent, wherein a modulation in the function of the human hematopoietic cells in the first humanized M-CSF mouse relative to the second humanized M-CSF mouse indicates that the agent modulates human hematopoietic cell function.
3. The method of claim 2 , wherein the first humanized M-CSF mouse and the second humanized M-CSF mouse are the same mouse, wherein the absence of the agent occurs prior to the contacting, and wherein a modulation in the function of the human hematopoietic cells after the contacting relative to the function of the human hematopoietic cells prior to the contacting indicates that the agent modulates human hematopoietic cell function.
4. The method of claim 2 , wherein the first humanized M-CSF mouse and the second humanized M-CSF mouse are different mice.
5. The method of claim 1 , comprising exposing the first and second humanized M-CSF mice to an amount of a human pathogen sufficient to produce an infection in the first and second humanized M-CSF mice, and measuring a parameter of the infection in the first humanized M-CSF mouse over time and a parameter of the infection in the second humanized M-CSF mouse over time, wherein the comparing comprises comparing the measured parameters to determine the in-vivo effect of the agent on the human pathogen.
6. The method of claim 5 , wherein the first humanized M-CSF mouse is contacted with the agent prior to exposing the first and second humanized M-CSF mice to the human pathogen.
7. The method of claim 5 , wherein the first humanized M-CSF mouse is contacted with the agent concurrently with the exposure to the human pathogen.
8. The method of claim 5 , wherein the first humanized M-CSF mouse is contacted with the agent subsequent to exposing the first and second humanized M-CSF mice to the human pathogen.
9. The method of claim 1 , wherein the first and second humanized M-CSF mice each comprise two copies of the nucleic acid sequence.
10. The method of claim 1 , wherein the first and second humanized M-CSF mice each comprise a same null mutation in at least one mouse M-CSF allele.
11. The method of claim 10 , wherein the null mutation is a deletion of mouse M-CSF exons 2-9.